Komori
Astellas Pharma (4503) · InitiativeAchieved

Termination of the License Agreement with Regeneron for VelocityMune Mouse Technology

First written in FY2019-Q1. 1 of 1 entries say "Achieved", first in FY2019-Q1. Latest entry: FY2019-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of the VelocImmune Mouse Technology Licensing Agreement with RegeneronA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019-Q1AchievedAnnual report

    「当社　リジェネロン社　米国　ベロシイミューン・マウスに関する技術　契約一時金及び一定率のロイヤリティー　2007年３月～2018年６月まで」

    リジェネロン社とのベロシティミューン・マウスに関する技術導入契約が2018年6月までで終了した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.